Retefast 18mg Injection
By Retefast
Rx
10ml Injection in a Vial

Composition
Reteplase(18mg)

Manufacturer - Cipla Ltd
Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400013

Expires on or after
July, 2026

liver
When using Retefast 18mg Injection, it is important to be cautious if you have liver disease. Patients with liver issues may require a dose adjustment for this medication. It is advised to consult your doctor before starting treatment with Retefast 18mg Injection. It is not recommended to use this injection in individuals with severe kidney disease.

kidney
Retefast 18mg Injection needs caution in patients with kidney disease. Dose adjustment may be necessary; consult your doctor. Not recommended for severe kidney disease patients.

alcohol
Consult your doctor when consuming alcohol with Retefast 18mg Injection.

driving
It is better to consult your doctor. Refrain from driving if you have symptoms impairing focus and reaction time when using Retefast 18mg Injection.

pregnancy
Retefast 18mg Injection is considered unsafe during pregnancy. Animal studies have shown potential harm to the developing baby. Your doctor will evaluate the benefits and risks before prescribing. Kindly consult your doctor before use.

breastfeeding
Retefast 18mg Injection is likely safe while breastfeeding, as minimal human data indicates low risk to the baby.
| Habit Forming | No |
| Chemical Class | Carboxylic Acid Derivative |
| Therapeutic Class | - |
| Action Class | Plasminogen Activators- Thrombolytics |
₹33000
Inclusive of all taxes
Content verified by

Dr. Abdullah Khan
MBBS - General Medicine
Last update on 01-Oct-2024
